Alimera Sciences, Inc. – NASDAQ:ALIM

Founder-led company
Financial Health
0
1
2
3
4
5
6
7
8
9

Alimera Sciences stock price monthly change

+79.49%
month

Alimera Sciences stock price quarterly change

+43.59%
quarter

Alimera Sciences stock price yearly change

+95.80%
year

Alimera Sciences key metrics

Market Cap
301.28M
Enterprise value
53.39M
P/E
-0.7
EV/Sales
0.66
EV/EBITDA
-3.69
Price/Sales
0.17
Price/Book
-0.68
PEG ratio
N/A
EPS
-1.46
Revenue
90.21M
EBITDA
-393K
Income
-21.41M
Revenue Q/Q
69.87%
Revenue Y/Y
61.74%
Profit margin
-33.71%
Oper. margin
-22.03%
Gross margin
85.34%
EBIT margin
-22.03%
EBITDA margin
-0.44%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Alimera Sciences stock price history

Alimera Sciences stock forecast

Alimera Sciences financial statements

Alimera Sciences, Inc. (NASDAQ:ALIM): Profit margin
Jun 2023 17.53M -10.02M -57.18%
Sep 2023 23.36M -1.35M -5.8%
Dec 2023 26.30M -3.78M -14.37%
Mar 2024 23.01M -6.25M -27.17%
Alimera Sciences, Inc. (NASDAQ:ALIM): Analyst Estimates
Sep 2025 29.1M 1.08M 3.74%
Oct 2025 29.96M 1.90M 6.35%
Dec 2025 33.03M 5.97M 18.1%
Mar 2026 28.6M -1.63M -5.71%
  • Analysts Price target

  • Financials & Ratios estimates

0%
Yield TTM
Alimera Sciences, Inc. (NASDAQ:ALIM): Payout ratio
Payout ratio 0%
Alimera Sciences, Inc. (NASDAQ:ALIM): Dividend Yield
2019
2020
2021
2022
2023 1.14%
Alimera Sciences, Inc. (NASDAQ:ALIM): Debt to assets
Jun 2023 154923000 108.69M 70.16%
Sep 2023 154192000 105.35M 68.33%
Dec 2023 153524000 107.35M 69.93%
Mar 2024 152485000 111.83M 73.34%
Alimera Sciences, Inc. (NASDAQ:ALIM): Cash Flow
Jun 2023 -5.99M -75.43M 87.12M
Sep 2023 -9.82M -4K -546K
Dec 2023 3.77M -85K -78K
Mar 2024 -566K -21K 2.96M

Alimera Sciences alternative data

Alimera Sciences, Inc. (NASDAQ:ALIM): Employee count
Aug 2023 150
Sep 2023 150
Oct 2023 150
Nov 2023 150
Dec 2023 150
Jan 2024 150
Feb 2024 150
Mar 2024 154
Apr 2024 154
May 2024 154
Jun 2024 154
Jul 2024 154

Alimera Sciences other data

5.96% -26.39%
of ALIM is owned by hedge funds
416.71K -1.84M
shares is hold by hedge funds

Alimera Sciences, Inc. (NASDAQ:ALIM): Insider trades (number of shares)
Period Buy Sel
Mar 2023 0 1200000
May 2023 1417018 0
Sep 2023 579000 579000
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
CALIGAN PARTNERS LP 10 percent owner
Common Stock 579,000 $3.39 $1,962,810
Sale
CALIGAN PARTNERS LP 10 percent owner
Common Stock, par value 0.01 per share (Common Stock) 579,000 $3.39 $1,962,810
Purchase
MORGAN ADAM director, 10 percent owner:
Common Stock 1,401,901 $1.7 $2,383,232
Purchase
MORGAN ADAM director, 10 percent owner:
Series B Convertible Preferred Stock 8,117 $1.7 $13,799
Purchase
MORGAN ADAM director, 10 percent owner:
Series B Convertible Preferred Stock 7,000 $1.7 $11,900
Sale
PALO ALTO INVESTORS LP 10 percent owner
Series A Convertible Preferred Stock 1,200,000 $1.56 $1,875,600
Sale
MORGAN STANLEY 10 percent owner
Common Stock 250,000 $4.55 $1,137,500
Purchase
EISWIRTH RICHARD S JR director, officer.. Common Stock 484 $4.5 $2,177
Purchase
EISWIRTH RICHARD S JR director, officer.. Common Stock 5,000 $4.8 $23,980
Purchase
EISWIRTH RICHARD S JR director, officer.. Common Stock 5,000 $4.89 $24,430
Patent
Application
Filling date: 2 May 2019 Issue date: 7 Nov 2019
Monday, 16 September 2024
globenewswire.com
globenewswire.com
Thursday, 12 September 2024
zacks.com
Tuesday, 10 September 2024
globenewswire.com
Tuesday, 6 August 2024
zacks.com
globenewswire.com
Saturday, 27 July 2024
globenewswire.com
Friday, 26 July 2024
prnewswire.com
Wednesday, 3 July 2024
globenewswire.com
Tuesday, 2 July 2024
prnewswire.com
Wednesday, 26 June 2024
accesswire.com
Tuesday, 25 June 2024
zacks.com
Monday, 24 June 2024
benzinga.com
prnewswire.com
investorplace.com
globenewswire.com
invezz.com
businesswire.com
Tuesday, 4 June 2024
globenewswire.com
Tuesday, 14 May 2024
seekingalpha.com
Zacks Investment Research
Wednesday, 13 March 2024
Zacks Investment Research
Thursday, 7 March 2024
Zacks Investment Research
Thursday, 10 August 2023
Zacks Investment Research
Wednesday, 2 August 2023
GlobeNewsWire
Thursday, 8 June 2023
Zacks Investment Research
Thursday, 1 June 2023
Zacks Investment Research
Thursday, 25 May 2023
Zacks Investment Research
Tuesday, 23 May 2023
Zacks Investment Research
Friday, 19 May 2023
Zacks Investment Research
  • When is Alimera Sciences's next earnings date?

    Unfortunately, Alimera Sciences's (ALIM) next earnings date is currently unknown.

  • Does Alimera Sciences pay dividends?

    No, Alimera Sciences does not pay dividends.

  • How much money does Alimera Sciences make?

    Alimera Sciences has a market capitalization of 301.28M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 49.19% to 80.75M US dollars.

  • What is Alimera Sciences's stock symbol?

    Alimera Sciences, Inc. is traded on the NASDAQ under the ticker symbol "ALIM".

  • What is Alimera Sciences's primary industry?

    Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.

  • How do i buy shares of Alimera Sciences?

    Shares of Alimera Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Alimera Sciences's key executives?

    Alimera Sciences's management team includes the following people:

    • Mr. Richard S. Eiswirth Jr. Pres, Chief Executive Officer & Director(age: 57, pay: $630,370)
    • Mr. David R. Holland Co-Founder, Chief Marketing Officer and Senior Vice President of Corporation Communications & Managed Markets(age: 61, pay: $429,360)
    • Dr. Philip Ashman Chief Operating Officer & Senior Vice President of Commercial Operations - Europe(age: 60, pay: $417,140)
    • Mr. Charles Daniel Myers Non-Executive Chairman & Consultant(age: 71, pay: $205,000)
  • Is Alimera Sciences founder-led company?

    Yes, Alimera Sciences is a company led by its founder Mr. David R. Holland.

  • How many employees does Alimera Sciences have?

    As Jul 2024, Alimera Sciences employs 154 workers.

  • When Alimera Sciences went public?

    Alimera Sciences, Inc. is publicly traded company for more then 5 years since IPO on 4 Nov 2019.

  • What is Alimera Sciences's official website?

    The official website for Alimera Sciences is alimerasciences.com.

  • Where are Alimera Sciences's headquarters?

    Alimera Sciences is headquartered at 6310 Town Square, Alpharetta, GA.

  • How can i contact Alimera Sciences?

    Alimera Sciences's mailing address is 6310 Town Square, Alpharetta, GA and company can be reached via phone at +678 990 5740.

Alimera Sciences company profile:

Alimera Sciences, Inc.

alimerasciences.com
Exchange:

NASDAQ

Full time employees:

154

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

6310 Town Square
Alpharetta, GA 30005

CIK: 0001267602
ISIN: US0162592028
CUSIP: 016259202